Parallel Advisors, LLC Autolus Therapeutics PLC Transaction History

Parallel Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$2.04 - $4.68 $2,003 - $4,595	-982 Closed	0 $0
Q1 2022 Apr 28, 2022	SELL	$3.52 - $5.46 $556 - $862	-158 Reduced 13.86%	982 $4,000
Q4 2021 Jan 20, 2022	BUY	$5.1 - $7.0 $4,896 - $6,720	960 Added 533.33%	1,140 $6,000
Q2 2021 Aug 06, 2021	BUY	$4.78 - $7.96 $860 - $1,432	180 New	180 $1,000
Q1 2021 Apr 23, 2021	SELL	$5.49 - $9.36 $1,257 - $2,143	-229 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$8.13 - $12.79 $1,861 - $2,928	229 New	229 $2,000
Q2 2020 Jul 16, 2020	SELL	$5.38 - $16.14 $1,737 - $5,213	-323 Closed	0 $0
Q1 2020 Apr 27, 2020	BUY	$4.2 - $13.0 $869 - $2,691	207 Added 178.45%	323 $1,000
Q4 2019 Jan 30, 2020	BUY	$11.13 - $16.28 $1,291 - $1,888	116 New	116 $2,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $274M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.